Enzymatically hydrolyzed fragments of collagen protein, typically 2-10 kDa. The most commercially successful peptide supplement category, with growing clinical evidence for skin, joint, and bone health.
Collagen peptides (also called hydrolyzed collagen or collagen hydrolysate) are small peptide fragments produced by enzymatic hydrolysis of native collagen protein. The source is typically bovine (cow), porcine (pig), marine (fish), or chicken collagen.
Unlike most protein supplements that are simply digested into individual amino acids, collagen peptides contain specific bioactive dipeptides and tripeptides — particularly Pro-Hyp (prolyl-hydroxyproline) and Hyp-Gly (hydroxyproline-glycine) — that survive digestion intact and circulate in the bloodstream, where they act as signaling molecules to stimulate the body's own collagen production.
Collagen peptides are not a single sequence but a mixture of fragments from the collagen triple helix. The characteristic Gly-X-Y repeat (where X is often Pro and Y is often Hyp) is preserved in many fragments. The presence of hydroxyproline (Hyp) — a post-translationally modified amino acid not found in the standard 20 — is the biochemical signature of collagen-derived peptides. Hydroxyproline is not available in the Design Lab calculator as it's not one of the standard 20 amino acids.
The critical insight about collagen peptides is that they are not simply providing raw materials. Specific bioactive fragments that resist complete digestion act as cell-signaling molecules. Pro-Hyp is the most studied — it accumulates in skin tissue after oral ingestion and directly stimulates fibroblast activity.
| Pathway | Effect | Significance |
|---|---|---|
| Pro-Hyp signaling | Binds fibroblast receptors to upregulate collagen I and III synthesis | Increases dermal collagen density and skin elasticity |
| Hyaluronic acid stimulation | Pro-Hyp stimulates hyaluronic acid synthase 2 (HAS2) | Improves skin hydration and joint lubrication |
| Chondrocyte activation | Collagen peptides stimulate cartilage cell metabolism | May slow cartilage degradation in osteoarthritis |
| Osteoblast stimulation | Increases osteoblast differentiation and activity | Supports bone mineral density, especially in postmenopausal women |
| MMP inhibition | May reduce matrix metalloproteinase activity | Slows collagen degradation in aging skin |
Collagen peptides have more human clinical trial data than most other peptides in this encyclopedia, driven by the nutraceutical industry.
| Study Area | Design | Key Findings | Evidence |
|---|---|---|---|
| Skin elasticity | DB-RCT, n=69 women, 8 weeks | 2.5-5g/day improved skin elasticity significantly vs placebo (Proksch 2014) | Level I |
| Skin hydration | DB-RCT, n=72, 12 weeks | Significant improvement in skin hydration, dermal collagen density, and collagen fibril organization | Level I |
| Wrinkle reduction | DB-RCT, n=114, 8 weeks | Significant reduction in eye wrinkle volume at 2.5g/day vs placebo | Level I |
| Joint pain (OA) | DB-RCT, n=250, 24 weeks | 10g/day reduced joint pain in athletes and OA patients; improved WOMAC scores | Level I-II |
| Bone density | DB-RCT, n=102 postmenopausal women, 12 months | 5g/day increased bone mineral density in spine and femoral neck vs placebo | Level I-II |
| Nail growth | DB-RCT, n=25, 24 weeks | 2.5g/day increased nail growth rate by 12% and decreased nail breakage by 42% | Level II |
Excellent safety profile: Decades of use as a food ingredient with no significant adverse effects. Generally Recognized as Safe (GRAS) status.
Allergen risk: May cause reactions in individuals with allergies to the source animal (bovine, marine, etc.). Marine collagen may affect people with fish/shellfish allergies.
Contaminants: Quality varies by manufacturer. Heavy metal contamination (particularly in marine sources) is a concern. Choose products with third-party testing.
Drug interactions: No known significant drug interactions. High proline content is generally safe.
| Jurisdiction | Status |
|---|---|
| FDA | GRAS status as a food ingredient. Marketed as a dietary supplement, not a drug. |
| EU | Approved as a Novel Food ingredient |
| WADA | Not banned |
| Market | Global collagen peptide market valued at ~$4.7B (2024), projected to reach $7.5B by 2030 |